Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Carcinoma, Hepatocellular 2Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Sarcoma, Synovial 1Neurofibrosarcoma 1Lymphoma 1Lung Neoplasms 1Liver Neoplasms 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Hereditary Sensory and Autonomic Neuropathies 1Dermatofibrosarcoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1Breast Neoplasms 1

Interventions

pembrolizumab 9avelumab 8Nivolumab 6Ipilimumab 4Radiotherapy 3durvalumab 2cemiplimab 2atezolizumab 2aldesleukin 2Specimen Handling 2Radiation 2Magnetic Resonance Spectroscopy 2Interferon-beta 2Cyclophosphamide 2Biopsy 2Bevacizumab 2tremelimumab 1sargramostim 1sapanisertib 1regorafenib 1prednylidene 1poly ICLC 1navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid 1lutetium Lu 177 dotatate 1interferon gamma-1b 1epacadostat 1efineptakin alfa 1deltacortene 1decitabine and cedazuridine drug combination 1bempegaldesleukin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Carcinoma, Merkel Cell × sapanisertib × Clear all
NCT02514824 2020-12-29

MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma

Dana-Farber Cancer Institute

Phase 1/2 Completed
9 enrolled 10 charts
Dermatologic

Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡